Allena Pharmaceuticals is focused on treating complex metabolic conditions that can lead to significant and costly health complications. The company aims to reduce the burden of toxic metabolites such as oxalate and uric acid. These metabolites are normal byproducts of cellular activity and are also derived from the typical diet. In certain circumstances, they can build up and lead to complications such as hyperoxaluria and kidney stones (nephrolithiasis) in the case of oxalate, or hyperuricemia and gout in the case of uric acid.
Latest funding size
Time since last funding
|almost 2 years|
|Pharmstandard, HBM Partners, Partner Fund Management, Inbio Ventures, Wellington Management, Fidelity Management and Research Company, Frazier Healthcare Partners, Bessemer Venture Partners, Third Rock Ventures|